[67] RANKL Signaling in Bone Lesions with Osteoclast-Like Giant Cells.

Ki-Yong Na, Kyu Yeoun Won, Ricardo K Kalil, Youn Wha Kim, Yong-Koo Park. Kyung Hee Medical Center, College of Medicine, Kyung Hee University, Seoul, Korea; Sarah Network of Rehabilitation Hospitals, San Paulo, Brazil

Background: The interaction between receptor activator of NF-κB (RANK), its ligand (RANKL), and the decoy receptor for RANKL, osteoprotegerin (OPG) performs a pivotal role in promoting osteoclast differentiation and activation leading to bone resorption. Giant cell tumors (GCT), chondroblastomas (CB), and aneurysmal bone cysts (ABC) harbor osteolytic lesions containing osteoclast-like giant cells.
Design: We selected 49 cases of GCT, 12 cases of CB, 6 cases of ABC, and 5 cases of metastatic giant cell tumors (including paired primary giant cell tumors). We evaluated RANK, RANKL, and OPG expression in giant cells of CB, GCT, and ABC via immunohistochemical methods. Additionally, the correlation between RANK, RANKL and OPG expression in these respective bone lesions was evaluated in this study.
Results: Our findings revealed that RANK, RANKL, and OPG expression in osteoclast-like giant cells differ significantly according to the disease entity (CB vs GCT vs ABC). CB showed significantly different RANK, RANKL, and OPG expression levels in comparison with GCT. And, CB evidenced significantly different RANK and OPG expression from ABC Additionally, our findings revealed a positive correlation between RANK and OPG in CB and GCT.
Conclusions: The expression of RANK, RANKL, and OPG in osteoclast-like giant cells differ significantly according to the disease entity (CB vs GCT vs ABC). Additionally, a positive correlation was revealed between RANK and OPG in CB and GCT.
Category: Bone & Soft Tissue

Tuesday, March 1, 2011 9:30 AM

Poster Session III # 13, Tuesday Morning

 

Close Window